Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 18/20 | 0.62 |
| ▸ | KCNJ3 | P48549 | 18/20 | 0.62 |
| ▸ | KCNJ5 | P48544 | 13/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16585479 | 0.84 | GRM5 (0.59) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL16585550 | 0.83 | NTRK1 (0.70) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL13234482 | 0.81 | KCNJ6 (0.84) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL4513114 | 0.81 | KCNJ6 (0.72) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL16585213 | 0.80 | MAPK13 (0.67) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23203519 | 0.78 | KCNJ6 (0.65) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL25793174 | 0.78 | KCNJ6 (0.69) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL16586811 | 0.78 | MAPK13 (0.47) | KCNJ6KCNJ3KCNJ5MAPK13MAPK12 | |
| SCHEMBL16585445 | 0.77 | MAPT (0.56) | KCNJ6KCNJ3KCNJ5MAPK13MAPK12 | |
| SCHEMBL13234475 | 0.76 | KCNJ6 (0.92) | KCNJ6KCNJ3KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | claimed |
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | claimed |
| EP-3046554-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2016-07-27 | — | — | EP | claimed |
| WO-2015042088-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP (US) | 2015-03-26 | — | — | WO | claimed |
| WO-2015039334-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-03-26 | — | — | WO | claimed |
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718782-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229804-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGF, NGFR, NTRK2 | KCNJ6 2471/4885KCNJ3 2323/4885KCNJ5 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.